Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: GlobeNewswire
Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026 with focus on durability and patient stratificationReported 14-day CRB-913 SAD/MAD data demonstrating potent and rapid weight loss of 2.9% with favorable GI safetyOn schedule to complete 12-week CRB-913 obesity study (n=240) in summer 2026 Completed $75 million public offering in Q4 2025 extending cash runway into 2028 NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. "Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health SummitGlobeNewswire
- How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals (CRBP) had its price target raised by Oppenheimer Holdings, Inc. from $53.00 to $57.00. They now have an "outperform" rating on the stock.MarketBeat
- Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance]Yahoo! Finance
CRBP
Earnings
- 3/9/26 - Beat
CRBP
Sec Filings
- 3/23/26 - Form EFFECT
- 3/11/26 - Form S-3
- 3/9/26 - Form 10-K
- CRBP's page on the SEC website